Woridwide, -40 million people live with Human Immunodeficiency Virus (HIV)-I disease and associated Acquired Immune Deficiency Syndrome (AIDS), half are women. HIV/AIDS has affected more women than any other disease over the past two decades. Women of color, particularly, African American and Hispanic American women carry the most significant burden of this disease. Clearly, HIV/AIDS in minorities and women will continue to be a significant burden and a critical area of Health Disparities research. Importantly, almost 50% of HIV/AIDS patients suffer from some neurocognitive impairment. Thus, studies that pertain to identification of novel biomarkers that predict disease progression and neurocognitive impairment are critical. Recent data demonstrate that sCD40L, a novel biomarker is significantly elevated in HIV-infected patients with neurocognitive impairment. However, no information is available regarding patterns of sCD40L changes in context of race and gender. This is important, as expression of disease characteristics in HIV/AIDS can be race- and/or gender-specific. Viral loads, metabolic parameters and body composition, plasma lipid levels etc. differ in the setting of specific race and gender. In this application, we propose to investigate the role of SCD40L as a prognostic marker for disease progression in HIV-1 neurological manifestations in the context of race and gender. Although limited to evaluations of race and gender as statistical risk factors, this work will synergize basic science with issues related to health disparities. Specifically, we will identify and analyze plasma sCD40L levels in a cohort of HIV+/- patients and correlate these to standard disease variables and cognitive function. All parameters will be correlated with each other and against neurocognitive measures to test the hypothesis that sCD40L levels correlate with neurocognitive impairment in the context of race and gender. We will also analyze the immune activation status of diverse patient leukocytes. Levels of sCD40L & other proinflammatory cytokines including TNF-a will be analyzed. Ours will be one ofthe first studies to fully describe the HIV-1-positive population characteristics in relation to specific cognitive outcomes, socioeconomic strata and sCD40L and will likelv vield data that will have direct therapeutic implications.
HIV/AIDS pandemic continues to be a global problem specifically for women &minorities and half the patients suffer from HIV-related conginitive problems. Few studies investigate novel biomarkers in the context of health disparities in HIV/AIDS patients. Results from this study will allow for predicting HIVassociated cognitive decline making these studies highly relevant for HIV/AIDS, minorities &women of color.
|Tan, Marissa; Mamun, Abdullah; Kitzman, Heather et al. (2017) Neighborhood Disadvantage and Allostatic Load in African American Women at Risk for Obesity-Related Diseases. Prev Chronic Dis 14:E119|
|Kitzman, Heather; Dodgen, Leilani; Mamun, Abdullah et al. (2017) Community-based participatory research to design a faith-enhanced diabetes prevention program: The Better Me Within randomized trial. Contemp Clin Trials 62:77-90|
|Bullock, Katura C (2017) Development, implementation, and evaluation of a service-learning series for pharmacy students using a public health tool. Curr Pharm Teach Learn 9:828-834|
|Gdowski, Andrew S; Ranjan, Amalendu; Sarker, Marjana R et al. (2017) Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine (Lond) 12:2083-2095|
|Maji, Sayantan; Chaudhary, Pankaj; Akopova, Irina et al. (2017) Exosomal Annexin II Promotes Angiogenesis and Breast Cancer Metastasis. Mol Cancer Res 15:93-105|
|Rajendiran, Smrithi; Gibbs, Lee D; Van Treuren, Timothy et al. (2016) MIEN1 is tightly regulated by SINE Alu methylation in its promoter. Oncotarget 7:65307-65319|
|Kpetemey, Marilyne; Chaudhary, Pankaj; Van Treuren, Timothy et al. (2016) MIEN1 drives breast tumor cell migration by regulating cytoskeletal-focal adhesion dynamics. Oncotarget 7:54913-54924|
|Mukerjee, Anindita; Ranjan, Anmalendu P; Vishwanatha, Jamboor K (2016) Targeted Nanocurcumin Therapy Using Annexin A2 Anitbody Improves Tumor Accumulation and Therapeutic Efficacy Against Highly Metastatic Breast Cancer. J Biomed Nanotechnol 12:1374-92|
|Kokate, Rutika A; Chaudhary, Pankaj; Sun, Xiangle et al. (2016) Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy. Nanomedicine (Lond) 11:479-94|
|Kpetemey, Marilyne; Dasgupta, Subhamoy; Rajendiran, Smrithi et al. (2015) MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression. Mol Cancer 14:156|
Showing the most recent 10 out of 25 publications